Glaxosmithkline Pharmaceuticals Ltd vs Strides Pharma Science Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The P/E Ratio of Glaxosmithkline Pharmaceuticals Ltd changed from 68.1 on March 2021 to 52.5 on March 2025 . This represents a CAGR of -5.07% over 5 yearsThe P/E Ratio of Strides Pharma Science Ltd changed from 28.2 on March 2021 to 1.7 on March 2025 . This represents a CAGR of -42.98% over 5 years The Market Cap of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 24401 crore on March 2021 to ₹ 48743 crore on March 2025 . This represents a CAGR of 14.84% over 5 yearsThe Market Cap of Strides Pharma Science Ltd changed from ₹ 7573 crore on March 2021 to ₹ 6165 crore on March 2025 . This represents a CAGR of -4.03% over 5 years The revenue of Glaxosmithkline Pharmaceuticals Ltd for the Dec '25 is ₹ 1091 crore as compare to the Sep '25 revenue of ₹ 1016 crore. This represent the growth of 7.4% The revenue of Strides Pharma Science Ltd for the Dec '25 is ₹ 1301 crore as compare to the Sep '25 revenue of ₹ 1247 crore. This represent the growth of 4.29% The ebitda of Glaxosmithkline Pharmaceuticals Ltd for the Dec '25 is ₹ 421.44 crore as compare to the Sep '25 ebitda of ₹ 371.94 crore. This represent the growth of 13.31% The ebitda of Strides Pharma Science Ltd for the Dec '25 is ₹ 339.48 crore as compare to the Sep '25 ebitda of ₹ 248.89 crore. This represent the growth of 36.4% The net profit of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 182.33 crore to ₹ 295.62 crore over 7 quarters. This represents a CAGR of 31.80% The net profit of Strides Pharma Science Ltd changed from ₹ 3349 crore to ₹ 208.12 crore over 7 quarters. This represents a CAGR of -79.56% The Dividend Payout of Glaxosmithkline Pharmaceuticals Ltd changed from 142.13 % on March 2021 to 99.54 % on March 2025 . This represents a CAGR of -6.88% over 5 yearsThe Dividend Payout of Strides Pharma Science Ltd changed from 28.66 % on March 2021 to 1.28 % on March 2025 . This represents a CAGR of -46.30% over 5 years .

About Glaxosmithkline Pharmaceuticals Ltd

GlaxoSmithKline Pharmaceuticals Limited was erstwhile incorporated as 'Glindia Limited' in November, 1924.
The Company' s name was changed to Glaxo (India) Limited' from Glindia Limited in year 1987 and further to 'GlaxoSmithKline Pharmaceuticals Limited' from Glaxo (India) Limited effective from October 22, 2001. GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma company to unite science, technology and talent to get ahead of disease together.
The Company is headquartered in Mumbai and it has six branch offices, one manufacturing facility at Nashik in Maharashtra, 20 contract manufacturing organisations (CMOs) with regional and sales hubs across India.
The Company is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals.

About Strides Pharma Science Ltd

Strides Pharma Science Limited was originally incorporated under the name 'Strides Arcolab Limited ' on June 28, 1990.
In FY 2016, Shasun Pharmaceuticals Limited merged with Strides Arcolab Limited forming a new identity 'Strides Shasun Limited', making it effective from 19 November, 2015 and name of the Company was changed to 'Strides Pharma Science Limited' from 'Strides Shasun Limited' effective on July 18, 2018. Strides Pharma Science is a global pharmaceutical company headquartered in Bengaluru, India.
The Company is an integrated manufacturer and exporter of Finished Pharmaceutical Dosage forms for both branded and generic.
It manufactures a very wide spectrum of ethical pharmaceutical products, OTC products and nutraceuticals.
Their dosage forms range includes tablets, capsules, soft gelatin capsules, parenterals and semisolids.

FAQs for the comparison of Glaxosmithkline Pharmaceuticals Ltd and Strides Pharma Science Ltd

Which company has a larger market capitalization, Glaxosmithkline Pharmaceuticals Ltd or Strides Pharma Science Ltd?

Market cap of Glaxosmithkline Pharmaceuticals Ltd is 39,566 Cr while Market cap of Strides Pharma Science Ltd is 9,552 Cr

What are the key factors driving the stock performance of Glaxosmithkline Pharmaceuticals Ltd and Strides Pharma Science Ltd?

The stock performance of Glaxosmithkline Pharmaceuticals Ltd and Strides Pharma Science Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Glaxosmithkline Pharmaceuticals Ltd and Strides Pharma Science Ltd?

As of May 4, 2026, the Glaxosmithkline Pharmaceuticals Ltd stock price is INR ₹2335.6. On the other hand, Strides Pharma Science Ltd stock price is INR ₹1036.35.

How do dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and Strides Pharma Science Ltd compare?

To compare the dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and Strides Pharma Science Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.